Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Daiichi Sankyo, Advenchen, AB Science, Immunicum, Novartis, Exelixis, Allarity, Onyx, DNAtrix

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 25+ key pharma and biotech companies are working on 28+ pipeline drugs in the Gastrointestinal Stromal Tumor therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Gastrointestinal Stromal Tumor (GIST) Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gastrointestinal Stromal Tumor Therapeutics Market.

The report provides a detailed description of the Gastrointestinal Stromal Tumor drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Gastrointestinal Stromal Tumor Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastrointestinal Stromal Tumor (GIST) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Gastrointestinal Stromal Tumor therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gastrointestinal Stromal Tumor treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Gastrointestinal Stromal Tumor drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Gastrointestinal Stromal Tumor treatment market.

Learn More about the Clinical and Commercial Development Activities in the Gastrointestinal Stromal Tumor Therapeutics Domain @
https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Gastrointestinal Stromal Tumor (GIST) Therapeutics Analysis
About 25 notable companies are actively engaged in developing therapies for Gastrointestinal Stromal Tumors (GIST). Jiangsu Hengrui Medicine distinguishes itself within this group, as its GIST drug candidates have progressed to the most advanced stage, Phase III.

Gastrointestinal Stromal Tumor (GIST) Companies in the Therapeutics Market Include:
Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., and Allarity Therapeutics are influential entities actively shaping the Gastrointestinal Stromal Tumor therapeutic space.

Emerging and Marketed Gastrointestinal Stromal Tumor (GIST) Therapies Covered in the Report Include:
• Famitinib: Jiangsu Hengrui Medicine
• Nilotinib: Novartis
• THE-630: Theseus Pharmaceuticals
• DS 6157: Daiichi Sankyo Company
And Many Others

Get an in-depth Assessment of the Emerging Therapies and Gastrointestinal Stromal Tumor Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Gastrointestinal Stromal Tumor Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Gastrointestinal Stromal Tumor Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Gastrointestinal Stromal Tumor Current Treatment Patterns
4. Gastrointestinal Stromal Tumor - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Gastrointestinal Stromal Tumor Late-Stage Products (Phase-III)
7. Gastrointestinal Stromal Tumor Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Gastrointestinal Stromal Tumor Discontinued Products
13. Gastrointestinal Stromal Tumor Product Profiles
14. Gastrointestinal Stromal Tumor Companies
15. Gastrointestinal Stromal Tumor Drugs
16. Dormant and Discontinued Products
17. Gastrointestinal Stromal Tumor Unmet Needs
18. Gastrointestinal Stromal Tumor Future Perspectives
19. Gastrointestinal Stromal Tumor Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.